Symbols / LLY Stock $1064.15 -1.67% Eli Lilly and Company

Healthcare • Drug Manufacturers - General • United States • NYQ
LLY (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - General
CEO Mr. David A. Ricks
Exch · Country NYQ · United States
Market Cap 948.95B
Enterprise Value 987.03B
Income 25.28B
Sales 72.25B
FCF (ttm) 9.16B
Book/sh 34.92
Cash/sh 5.92
Employees 50,000
Insider 10d —
IPO Jun 01, 1972
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 22.13%
P/E 37.74
Forward P/E 23.93
PEG 1.45
P/S 13.13
P/B 30.48
P/C —
EV/EBITDA 27.25
EV/Sales 13.66
Quick Ratio 0.72
Current Ratio 1.50
Debt/Eq 139.01
LT Debt/Eq —
EPS (ttm) 28.20
EPS next Y 44.47
EPS Growth 169.90%
Revenue Growth 55.50%
EPS Gr Q/Q 168.10%
Rev Gr Q/Q —
Earnings (next) 2026-08-05
Earnings (prior) 2026-04-30
ROA 20.74%
ROE 107.46%
ROIC —
Gross Margin 82.83%
Oper. Margin 49.39%
Profit Margin 34.99%
Shs Outstand 891.74M
Shs Float 889.33M
Insider Own 0.16%
Instit Own 85.32%
Short Float 0.95%
Short Ratio 2.44
Short Interest 8.43M
52W High 1,149.10
vs 52W High -7.39%
52W Low 623.78
vs 52W Low 70.60%
Beta 0.48
Impl. Vol. 46.09%
Rel Volume 0.57
Avg Volume 3.09M
Volume 1.77M
Target (mean) $1,215.10
Tgt Median $1,251.00
Tgt Low $850.00
Tgt High $1,500.00
# Analysts 29
Recom Buy
Prev Close $1,082.20
Price $1,064.15
Change -1.67%
About

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$1215.10
Mean price target
2. Current target
$1064.15
Latest analyst target
3. DCF / Fair value
$184.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1064.15
Low
$850.00
High
$1500.00
Mean
$1215.10

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-26 main B of A Securities Buy → Buy $1251
2026-05-05 main Barclays Overweight → Overweight $1400
2026-05-05 reit Guggenheim Buy → Buy $1183
2026-05-04 reit Wolfe Research Outperform → Outperform $1325
2026-05-01 main Cantor Fitzgerald Overweight → Overweight $1230
2026-04-22 main Guggenheim Buy → Buy $1183
2026-04-10 main Morgan Stanley Overweight → Overweight $1327
2026-04-02 main B of A Securities Buy → Buy $1294
2026-03-30 main Guggenheim Buy → Buy $1163
2026-03-17 down HSBC Hold → Reduce $850
2026-02-25 init RBC Capital — → Outperform $1250
2026-02-20 init Barclays — → Overweight $1350
2026-02-10 up Freedom Broker Hold → Buy $1200
2026-02-09 main Deutsche Bank Buy → Buy $1285
2026-02-05 main JP Morgan Overweight → Overweight $1300
2026-02-05 main Cantor Fitzgerald Overweight → Overweight $1205
2026-02-05 main Wells Fargo Overweight → Overweight $1280
2026-02-05 main Morgan Stanley Overweight → Overweight $1313
2026-02-02 main Freedom Broker Hold → Hold $1050
2026-01-20 main Guggenheim Buy → Buy $1161
News
RSS: Latest LLY news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-18 LUCIANO JUAN R Director — 16 $988.09 $15,917
2026-05-18 FYRWALD J. ERIK Director — 10 $988.09 $9,916
2026-05-18 ALVAREZ RALPH Director — 12 $988.09 $12,416
2026-05-18 SULZBERGER GABRIELLE Director — 5 $988.09 $4,958
2026-05-06 LILLY ENDOWMENT, INC. Beneficial Owner of more than 10% of a Class of Security — 15,828 $995.22 $15,754,537
2026-04-20 LUCIANO JUAN R Director — 17 $919.90 $15,917
2026-04-20 FYRWALD J. ERIK Director — 10 $919.90 $9,917
2026-04-20 ALVAREZ RALPH Director — 13 $919.90 $12,417
2026-04-20 SULZBERGER GABRIELLE Director — 5 $919.90 $4,958
2026-03-16 LUCIANO JUAN R Director — 16 $989.12 $15,917
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
65,179.00
+44.70%
45,043.00
+32.00%
34,124.00
+19.56%
28,541.40
Operating Revenue
65,179.00
+44.70%
45,043.00
+32.00%
34,124.00
+19.56%
28,541.40
Cost Of Revenue
11,052.00
+31.29%
8,418.00
+18.86%
7,082.00
+6.82%
6,629.80
Reconciled Cost Of Revenue
11,052.00
+31.29%
8,418.00
+18.86%
7,082.00
+6.82%
6,629.80
Gross Profit
54,127.00
+47.79%
36,625.00
+35.44%
27,042.00
+23.41%
21,911.60
Operating Expense
24,431.00
+24.74%
19,585.00
+17.16%
16,717.00
+22.64%
13,631.20
Research And Development
13,337.00
+21.34%
10,991.00
+18.02%
9,313.00
+29.51%
7,190.80
Selling General And Administration
11,094.00
+29.09%
8,594.00
+16.07%
7,404.00
+14.96%
6,440.40
General And Administrative Expense
—
8,593.80
+16.08%
7,403.10
+14.95%
6,440.40
Salaries And Wages
—
-461.70
+0.04%
-461.90
-23.87%
-372.90
Other Gand A
—
8,593.80
+16.08%
7,403.10
+14.95%
6,440.40
Total Expenses
35,483.00
+26.71%
28,003.00
+17.66%
23,799.00
+17.46%
20,261.00
Operating Income
29,696.00
+74.27%
17,040.00
+65.04%
10,325.00
+24.69%
8,280.40
EBITDA
31,693.00
+68.52%
18,807.00
+58.68%
11,852.00
+36.85%
8,660.50
Normalized EBITDA
35,087.00
+52.90%
22,948.00
+45.98%
15,720.00
+53.75%
10,224.30
Reconciled Depreciation
1,997.00
+13.02%
1,767.00
+15.72%
1,527.00
+0.30%
1,522.50
EBIT
29,696.00
+74.27%
17,040.00
+65.04%
10,325.00
+44.65%
7,138.00
Total Unusual Items
-3,394.00
+18.04%
-4,141.00
-7.06%
-3,868.00
-147.35%
-1,563.80
Total Unusual Items Excluding Goodwill
-3,394.00
+18.04%
-4,141.00
-7.06%
-3,868.00
-147.35%
-1,563.80
Special Income Charges
-3,394.00
+18.04%
-4,141.00
-7.06%
-3,868.00
-235.44%
-1,153.10
Other Special Charges
2,910.00
-11.28%
3,280.00
-13.68%
3,800.00
+318.27%
908.50
Impairment Of Capital Assets
—
—
—
—
Restructuring And Mergern Acquisition
2,910.00
-11.28%
3,280.00
+7108.79%
45.50
+97.83%
23.00
Write Off
484.00
-43.79%
861.00
+1166.18%
68.00
-72.20%
244.60
Net Income
20,640.00
+94.90%
10,590.00
+102.10%
5,240.00
-16.09%
6,244.80
Pretax Income
25,731.00
+102.93%
12,680.00
+93.47%
6,554.00
-3.71%
6,806.40
Net Non Operating Interest Income Expense
—
-605.40
-93.85%
-312.30
-16.18%
-268.80
Interest Expense Non Operating
—
780.60
+60.65%
485.90
+46.53%
331.60
Net Interest Income
—
-605.40
-93.85%
-312.30
-16.18%
-268.80
Interest Expense
—
780.60
+60.65%
485.90
+46.53%
331.60
Interest Income Non Operating
—
175.20
+0.92%
173.60
+176.43%
62.80
Interest Income
—
175.20
+0.92%
173.60
+176.43%
62.80
Other Income Expense
-3,965.00
+9.06%
-4,360.00
-15.62%
-3,771.00
-212.89%
-1,205.20
Other Non Operating Income Expenses
-571.00
-160.73%
-219.00
-325.77%
97.00
-72.95%
358.60
Gain On Sale Of Security
—
-49.50
-145.05%
-20.20
+95.08%
-410.70
Gain On Sale Of Business
—
—
—
—
Tax Provision
5,091.00
+143.59%
2,090.00
+59.06%
1,314.00
+133.97%
561.60
Tax Rate For Calcs
0.00
+20.04%
0.00
-18.00%
0.00
+142.17%
0.00
Tax Effect Of Unusual Items
-671.52
+1.62%
-682.55
+12.21%
-777.47
-499.00%
-129.80
Net Income Including Noncontrolling Interests
20,640.00
+94.90%
10,590.00
+102.10%
5,240.00
-16.09%
6,244.80
Net Income From Continuing Operation Net Minority Interest
20,640.00
+94.90%
10,590.00
+102.10%
5,240.00
-16.09%
6,244.80
Net Income From Continuing And Discontinued Operation
20,640.00
+94.90%
10,590.00
+102.10%
5,240.00
-16.09%
6,244.80
Net Income Continuous Operations
20,640.00
+94.90%
10,590.00
+102.10%
5,240.00
-16.09%
6,244.80
Net Income Discontinuous Operations
—
—
—
—
Normalized Income
23,362.48
+66.30%
14,048.45
+68.64%
8,330.53
+8.49%
7,678.80
Net Income Common Stockholders
20,640.00
+94.90%
10,590.00
+102.10%
5,240.00
-16.09%
6,244.80
Diluted EPS
22.95
+95.99%
11.71
+101.90%
5.80
-11.75%
6.57
Basic EPS
23.07
+95.50%
11.80
+102.50%
5.83
-11.34%
6.57
Basic Average Shares
894.80
-0.31%
897.54
-0.20%
899.38
-5.35%
950.18
Diluted Average Shares
899.30
-0.53%
904.06
+0.09%
903.28
-4.94%
950.18
Diluted NI Availto Com Stockholders
20,640.00
+94.90%
10,590.00
+102.10%
5,240.00
-16.09%
6,244.80
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
112,476.00
+42.89%
78,715.00
+22.98%
64,006.30
+29.33%
49,489.80
Current Assets
55,629.00
+69.91%
32,740.00
+27.26%
25,727.00
+42.65%
18,034.50
Cash Cash Equivalents And Short Term Investments
7,268.00
+122.40%
3,268.00
+11.62%
2,927.70
+32.37%
2,211.80
Cash And Cash Equivalents
7,268.00
+122.40%
3,268.00
+15.94%
2,818.60
+36.36%
2,067.00
Cash Equivalents
—
—
1,088.40
+65.56%
657.40
Cash Financial
—
—
1,730.20
+22.74%
1,409.60
Other Short Term Investments
—
154.80
+41.89%
109.10
-24.65%
144.80
Receivables
20,155.00
+51.82%
13,276.00
+17.11%
11,336.20
+32.45%
8,558.90
Accounts Receivable
17,760.00
+61.37%
11,006.00
+21.07%
9,090.50
+31.82%
6,896.00
Gross Accounts Receivable
—
11,020.60
+21.04%
9,105.30
+31.73%
6,912.00
Allowance For Doubtful Accounts Receivable
—
-14.90
-0.68%
-14.80
+7.50%
-16.00
Other Receivables
2,395.00
+5.51%
2,270.00
+1.08%
2,245.70
+35.05%
1,662.90
Inventory
13,744.00
+81.10%
7,589.00
+31.46%
5,772.80
+33.95%
4,309.70
Raw Materials
3,587.00
+54.21%
2,326.00
+42.69%
1,630.10
+103.28%
801.90
Work In Process
8,183.00
+105.65%
3,979.00
+22.48%
3,248.60
+25.06%
2,597.70
Finished Goods
1,931.00
+58.15%
1,221.00
+54.23%
791.70
-12.15%
901.20
Prepaid Assets
14,315.00
+71.62%
8,341.00
+50.54%
5,540.80
+88.03%
2,946.80
Other Current Assets
147.00
-44.74%
266.00
+77.93%
149.50
+1947.95%
7.30
Total Non Current Assets
56,847.00
+23.64%
45,976.00
+20.11%
38,279.30
+21.69%
31,455.30
Net PPE
24,674.00
+44.27%
17,103.00
+32.44%
12,913.60
+27.30%
10,144.00
Gross PPE
37,234.00
+28.87%
28,892.00
+20.32%
24,012.90
+17.84%
20,377.40
Accumulated Depreciation
-12,560.00
-6.54%
-11,789.00
-6.21%
-11,099.30
-8.46%
-10,233.40
Properties
0.00
0.00
0.00
0.00
Land And Improvements
647.00
+69.37%
382.00
+19.45%
319.80
+24.63%
256.60
Buildings And Improvements
10,088.00
+14.55%
8,807.00
+6.36%
8,280.00
+4.60%
7,915.90
Construction In Progress
13,013.00
+57.83%
8,245.00
+62.17%
5,084.10
+81.67%
2,798.60
Other Properties
13,486.00
+17.70%
11,458.00
+10.93%
10,329.00
+9.81%
9,406.30
Goodwill And Other Intangible Assets
12,420.00
+4.05%
11,936.00
+0.76%
11,846.30
+5.02%
11,279.60
Goodwill
5,898.00
+2.22%
5,770.00
+16.81%
4,939.70
+21.28%
4,073.00
Other Intangible Assets
6,522.00
+5.77%
6,166.00
-10.72%
6,906.60
-4.16%
7,206.60
Investments And Advances
2,802.00
-12.87%
3,216.00
+5.37%
3,052.20
+5.18%
2,901.80
Long Term Equity Investment
2,134.00
+6.33%
2,007.00
+27.81%
1,570.30
+24.68%
1,259.50
Non Current Deferred Assets
9,959.00
+24.47%
8,001.00
+46.08%
5,477.30
+96.12%
2,792.90
Non Current Deferred Taxes Assets
9,959.00
+24.47%
8,001.00
+46.08%
5,477.30
+96.12%
2,792.90
Other Non Current Assets
6,992.00
+22.24%
5,720.00
+14.63%
4,989.90
+15.05%
4,337.00
Total Liabilities Net Minority Interest
85,941.00
+33.36%
64,443.00
+21.26%
53,142.60
+37.27%
38,714.40
Current Liabilities
35,228.00
+24.15%
28,376.00
+3.97%
27,293.20
+59.25%
17,138.20
Payables And Accrued Expenses
22,761.00
+54.12%
14,768.00
-4.46%
15,457.00
+31.75%
11,731.90
Payables
5,379.00
+66.58%
3,229.00
-14.30%
3,768.00
+27.82%
2,947.80
Accounts Payable
5,379.00
+66.58%
3,229.00
+24.25%
2,598.80
+34.61%
1,930.60
Dividends Payable
—
1,346.30
+15.15%
1,169.20
+14.94%
1,017.20
Current Accrued Expenses
17,382.00
+50.64%
11,539.00
-1.28%
11,689.00
+33.07%
8,784.10
Employee Benefits
—
1,300.50
-9.61%
1,438.80
+10.24%
1,305.10
Pensionand Other Post Retirement Benefit Plans Current
2,375.00
+13.42%
2,094.00
+26.88%
1,650.40
+55.73%
1,059.80
Total Tax Payable
—
—
—
475.10
Income Tax Payable
—
—
—
475.10
Current Debt And Capital Lease Obligation
1,635.00
-68.05%
5,117.00
-25.89%
6,904.50
+359.96%
1,501.10
Current Debt
1,635.00
-68.05%
5,117.00
-25.89%
6,904.50
+359.96%
1,501.10
Other Current Liabilities
8,457.00
+32.20%
6,397.00
+94.95%
3,281.30
+15.32%
2,845.40
Total Non Current Liabilities Net Minority Interest
50,713.00
+40.61%
36,067.00
+39.53%
25,849.40
+19.81%
21,576.20
Long Term Debt And Capital Lease Obligation
40,868.00
+43.26%
28,527.00
+55.71%
18,320.80
+24.31%
14,737.50
Long Term Debt
40,868.00
+43.26%
28,527.00
+55.71%
18,320.80
+24.31%
14,737.50
Non Current Pension And Other Postretirement Benefit Plans
—
1,300.50
-9.61%
1,438.80
+10.24%
1,305.10
Tradeand Other Payables Non Current
5,875.00
+44.67%
4,061.00
+5.50%
3,849.20
+3.76%
3,709.60
Non Current Deferred Liabilities
—
—
—
87.30
Non Current Deferred Taxes Liabilities
—
—
—
87.30
Other Non Current Liabilities
3,970.00
+14.11%
3,479.00
+55.27%
2,240.60
+22.84%
1,824.00
Stockholders Equity
26,535.00
+85.92%
14,272.00
+32.49%
10,771.90
+1.15%
10,649.80
Common Stock Equity
26,535.00
+85.92%
14,272.00
+32.49%
10,771.90
+1.15%
10,649.80
Capital Stock
590.00
-0.34%
592.00
-0.27%
593.60
-0.08%
594.10
Common Stock
590.00
-0.34%
592.00
-0.27%
593.60
-0.08%
594.10
Share Issued
944.80
-0.33%
947.90
-0.20%
949.78
-0.09%
950.63
Ordinary Shares Number
894.80
-0.31%
897.54
-0.20%
899.38
-5.35%
950.18
Treasury Shares Number
50.00
-0.72%
50.37
-0.07%
50.40
+11100.44%
0.45
Additional Paid In Capital
7,346.00
-1.25%
7,439.00
+2.60%
7,250.40
+4.75%
6,921.40
Retained Earnings
24,470.00
+80.66%
13,545.00
+31.35%
10,312.30
+2.69%
10,042.60
Gains Losses Not Affecting Retained Earnings
-2,880.00
+33.36%
-4,322.00
+0.12%
-4,327.00
-12.55%
-3,844.60
Treasury Stock
—
49.50
+11.99%
44.20
-12.48%
50.50
Minority Interest
—
79.50
-13.40%
91.80
-26.91%
125.60
Other Equity Adjustments
-2,880.00
+33.36%
-4,322.00
+0.12%
-4,327.00
-12.55%
-3,844.60
Total Equity Gross Minority Interest
26,535.00
+85.92%
14,272.00
+31.37%
10,863.70
+0.82%
10,775.40
Total Capitalization
67,403.00
+57.49%
42,799.00
+47.11%
29,092.70
+14.60%
25,387.30
Working Capital
20,401.00
+367.48%
4,364.00
+378.64%
-1,566.20
-274.74%
896.30
Invested Capital
69,038.00
+44.08%
47,916.00
+33.11%
35,997.20
+33.88%
26,888.40
Total Debt
42,503.00
+26.33%
33,644.00
+33.37%
25,225.30
+55.34%
16,238.60
Net Debt
35,235.00
+16.00%
30,376.00
+35.57%
22,406.70
+58.11%
14,171.60
Net Tangible Assets
14,115.00
+504.24%
2,336.00
+317.42%
-1,074.40
-70.59%
-629.80
Tangible Book Value
14,115.00
+504.24%
2,336.00
+317.42%
-1,074.40
-70.59%
-629.80
Available For Sale Securities
668.00
-44.75%
1,209.00
-4.62%
1,267.60
-11.26%
1,428.40
Held To Maturity Securities
—
211.40
-1.35%
214.30
+0.19%
213.90
Inventories Adjustments Allowances
—
62.90
-38.57%
102.40
+1050.56%
8.90
Investmentin Financial Assets
668.00
-44.75%
1,209.00
-18.42%
1,481.90
-9.77%
1,642.30
Other Equity Interest
-2,991.00
-0.30%
-2,982.00
+1.04%
-3,013.20
+0.00%
-3,013.20
Other Inventories
43.00
-31.75%
63.00
-38.48%
102.40
+1050.56%
8.90
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
16,813.00
+90.67%
8,818.00
+107.97%
4,240.00
-44.11%
7,585.70
Cash Flow From Continuing Operating Activities
16,813.00
+90.67%
8,818.00
+107.97%
4,240.00
-44.11%
7,585.70
Net Income From Continuing Operations
20,640.00
+94.90%
10,590.00
+102.10%
5,240.00
-16.09%
6,244.80
Depreciation Amortization Depletion
1,997.00
+13.02%
1,767.00
+15.72%
1,527.00
+0.30%
1,522.50
Depreciation And Amortization
1,997.00
+13.02%
1,767.00
+15.72%
1,527.00
+0.30%
1,522.50
Other Non Cash Items
3,530.00
-14.03%
4,106.00
-0.32%
4,119.00
+200.70%
1,369.80
Stock Based Compensation
626.00
-3.10%
646.00
+2.70%
629.00
+69.50%
371.10
Deferred Tax
-1,707.00
+36.38%
-2,683.00
-14.61%
-2,341.00
-7.13%
-2,185.20
Deferred Income Tax
-1,707.00
+36.38%
-2,683.00
-14.61%
-2,341.00
-7.13%
-2,185.20
Operating Gains Losses
-180.00
+19.64%
-224.00
+88.08%
-1,879.00
-813.09%
263.50
Gain Loss On Sale Of PPE
-180.00
+19.64%
-224.00
+88.08%
-1,879.00
-1100.64%
-156.50
Change In Working Capital
-8,093.00
-50.32%
-5,384.00
-76.24%
-3,055.00
-381775.00%
-0.80
Change In Receivables
-7,000.00
-224.83%
-2,155.00
+12.08%
-2,451.00
-718.09%
-299.60
Change In Inventory
-4,671.00
-86.32%
-2,507.00
-75.93%
-1,425.00
-137.62%
-599.70
Change In Prepaid Assets
-6,609.00
-98.41%
-3,331.00
+3.53%
-3,453.00
-335.16%
-793.50
Change In Payables And Accrued Expense
10,187.00
+290.46%
2,609.00
-38.96%
4,274.00
+152.60%
1,692.00
Change In Payable
10,187.00
+290.46%
2,609.00
-38.96%
4,274.00
+152.60%
1,692.00
Change In Account Payable
10,187.00
+290.46%
2,609.00
-38.96%
4,274.00
+152.60%
1,692.00
Change In Other Current Assets
—
—
-3,453.40
-335.21%
-793.50
Investing Cash Flow
-10,972.00
-17.95%
-9,302.00
-30.04%
-7,153.00
-90.09%
-3,762.90
Cash Flow From Continuing Investing Activities
-10,972.00
-17.95%
-9,302.00
-30.04%
-7,153.00
-90.09%
-3,762.90
Net PPE Purchase And Sale
-7,841.00
-55.02%
-5,058.00
-46.69%
-3,448.00
-85.95%
-1,854.30
Purchase Of PPE
-7,841.00
-55.02%
-5,058.00
-46.69%
-3,448.00
-85.95%
-1,854.30
Capital Expenditure
-10,849.00
-29.09%
-8,404.00
-13.69%
-7,392.00
-147.61%
-2,985.30
Net Investment Purchase And Sale
319.00
+205.28%
-303.00
-35.87%
-223.00
+8.61%
-244.00
Purchase Of Investment
-645.00
+4.73%
-677.00
+7.39%
-731.00
-3.31%
-707.60
Sale Of Investment
964.00
+157.75%
374.00
-26.38%
508.00
+9.58%
463.60
Net Business Purchase And Sale
-661.00
+30.27%
-948.00
+9.20%
-1,044.00
-219.07%
-327.20
Purchase Of Business
-661.00
+30.27%
-948.00
+9.20%
-1,044.00
-219.07%
-327.20
Gain Loss On Sale Of Business
—
—
—
—
Net Intangibles Purchase And Sale
-2,790.00
-1.64%
-2,745.00
-17.31%
-2,340.00
-126.04%
-1,035.20
Purchase Of Intangibles
-3,008.00
+10.10%
-3,346.00
+15.16%
-3,944.00
-248.72%
-1,131.00
Net Other Investing Changes
1.00
+100.40%
-248.00
-153.06%
-98.00
+67.57%
-302.20
Financing Cash Flow
-2,213.00
-279.92%
1,230.00
-64.82%
3,496.00
+164.66%
-5,406.70
Cash Flow From Continuing Financing Activities
-2,213.00
-279.92%
1,230.00
-64.82%
3,496.00
+164.66%
-5,406.70
Net Issuance Payments Of Debt
8,051.00
-9.55%
8,901.00
+2.90%
8,650.00
+14051.61%
-62.00
Issuance Of Debt
13,167.00
+15.33%
11,417.00
+188.38%
3,959.00
0.00
Repayment Of Debt
-778.00
-17.17%
-664.00
0.00
+100.00%
-1,560.00
Long Term Debt Issuance
13,167.00
+15.33%
11,417.00
+188.38%
3,959.00
0.00
Long Term Debt Payments
-778.00
-17.17%
-664.00
0.00
+100.00%
-1,560.00
Net Long Term Debt Issuance
12,389.00
+15.21%
10,753.00
+171.61%
3,959.00
+353.78%
-1,560.00
Net Short Term Debt Issuance
-4,338.00
-134.23%
-1,852.00
-139.48%
4,691.00
+213.15%
1,498.00
Net Common Stock Issuance
-4,108.00
-64.32%
-2,500.00
-233.33%
-750.00
+50.00%
-1,500.00
Common Stock Payments
-4,108.00
-64.32%
-2,500.00
-233.33%
-750.00
+50.00%
-1,500.00
Common Stock Dividend Paid
-5,384.00
-15.04%
-4,680.00
-15.02%
-4,069.00
-15.08%
-3,535.80
Cash Dividends Paid
-5,384.00
-15.04%
-4,680.00
-15.02%
-4,069.00
-15.08%
-3,535.80
Repurchase Of Capital Stock
-4,108.00
-64.32%
-2,500.00
-233.33%
-750.00
+50.00%
-1,500.00
Net Other Financing Charges
-772.00
-57.23%
-491.00
-46.57%
-335.00
-8.45%
-308.90
Changes In Cash
3,628.00
+386.33%
746.00
+27.96%
583.00
+136.81%
-1,583.90
Effect Of Exchange Rate Changes
372.00
+225.25%
-297.00
-275.74%
169.00
+200.84%
-167.60
Beginning Cash Position
3,268.00
+15.93%
2,819.00
+36.38%
2,067.00
-45.87%
3,818.50
End Cash Position
7,268.00
+122.40%
3,268.00
+15.93%
2,819.00
+36.38%
2,067.00
Free Cash Flow
5,964.00
+1340.58%
414.00
+113.13%
-3,152.00
-168.52%
4,600.40
Change In Income Tax Payable
—
—
—
346.60
Change In Tax Payable
—
—
—
346.60
Sale Of Business
—
—
—
—
Sale Of Intangibles
218.00
-63.73%
601.00
-62.53%
1,604.00
+1574.32%
95.80
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category